The invention relates to compounds of the formula I: wherein ring C is as defined herein, for example indolyl, indazolyl or azaindolyl； Z is -O-, -NH- or -S-； n is 0-5； m is 0-3； R 1 and R 2 are defined herein including groups: (i) Q 1 X 1 wherein Q 1 and X 1 are as defined herein； (ii) Q15W 3 wherein Q 15 and W 3 are as defined herein, (iii) Q 21 W 4 C 1-5 alkylX 1 - wherein Q 21 , W 4 and X 1 are as defined herein, (iv) Q 28 C 1-5 alkylX 1 -, Q 28 C 2-5 alkenylX 1- or Q 28 C 2-5 alkynylX 1 - wherein Q 28 and X 1 are as defined herein and (v) Q 29 C 1-5 alkylX 1 -, Q 29 C 2-5 alkenylX 1 - or Q 29 C 2-5 alkynylx 1 - wherein Q 29 and X 1 are as defined herein； R 2 can also be 6,7-methylenedioxy or 6,7-ethylenedioxy； and salts thereof； their use in the manufacture of a medicament for use in the production of an antiangiogenic and/or vascular permeability reducing effect in warm-blooded animals； processes for the preparation of such compounds； intermediates used in such processes； processes for making such intermediates； pharmaceutical compositions containing a compound of formula I or a pharmaceutically acceptable salt thereof and methods of treating disease states involving angiogenesis by administering a compound of formula I or a pharmaceutically acceptable salt thereof. The compounds of formula I inhibit the effects of VEGF, a property of value in the treatment of a number of disease states including cancer and rheumatoid arthritis.
